Efficacy of Bifidobacterium combined with ulinastatin and octreotide in treatment of severe acute pancreatitis
Xu Jun-yan
Cheng Hao-nan
Wang Jin
Li Hui
Zhao Xiao-guang
Shi Shu-wei
Zhang Yi-qing
Zhang Chen-xi
Abstract：Objective To explore the efficacy of bifidobacterium quadruple viable bacteria tablets combined with ulinastatin and octreotide in the treatment of severe acute pancreatitis(SAP).Methods A total of 86 patients with SAP admitted to Jiaozuo People's Hospital affiliated to Xinxiang Medical College from January 2023 to January 2024 were selected and divided into the control group and observation group by random number table method.The patients in the control group received ulinastatin and oc-treotide,whereas those in the observation group additionally received bifidobacterium quadruple viable bacteria tablets.The clinical efficacy,symptom remission time and hospitalization time,serum inflammatory factor(tumor necrosis factor-α(TNF-α),C-reactive protein(CRP),interleukin-6(IL-6))levels,intestinal mucosal barrier function indicator(D-lactic acid,diamine oxidase(DAO),endo-toxin(ET))levels,pancreatic function indicator(amylase(AMY),lipase(LIPA),insulin(INS))levels before and after treatment and the occurrence of adverse reactions were compared between the two groups.Results The total effective rate was 93.02%(40/43)in the observation group,which was higher than 76.74%of the control group(33/43)(χ2=4.440,P<0.05).The symptom of bloat-ing,abdominal pain,and vomiting remission time and hospitalization time of the observation((3.96±0.83)d,(3.79±0.91)d,(2.89±0.71)d,(6.83±2.04)d)were shorter than those of the control((4.87±1.19)d,(4.62±1.12)d,(3.54±0.83)d,(12.87±4.18)d)(t=4.113,3.772,3.902,8.515,all P<0.05).After treatment,the levels of TNF-α,IL-6,and CRP in both groups decreased,and they were lower in the observation group((35.42±10.37)μg·L-1,(82.43±25.05)ng·L-1,(21.87±5.72)mg·L-1)than in the control((57.87±17.68)μg·L-1,(118.47±35.18)ng·L-1,(37.61±7.18)mg·L-1)(t=7.182,5.472,11.243,all P<0.05).The levels of D-lactic acid,DAO,and ET in both groups decreased,and they were lower in the observation group((5.82±0.71)μg·L-1,(2.27±0.45)U·mL-1,(0.17±0.05)EU·mL-1)than in the control((8.67±1.28)μg·L-1,(3.83±0.76)U·mL-1,(0.26±0.08)EU·mL-1)(t=12.768,11.582,6.256,all P<0.05).The AMY and LIPA levels in both groups decreased,while the INS levels increased.The AMY and LIPA levels in the observation group((65.52±5.34)U·L-1,(6.57±1.75)U·L-1)were lower than those in the control((87.41±7.58)U·L-1,(8.83±1.96)U·L-1)but the INS levels in the observation group((6.75±0.82)mU·L-1)was higher than that in the control((5.21±0.78)mU·L-1)(t=15.481,5.640,8.923,all P<0.05).The incidence of adverse reactions was 9.3%(4/43)in the observation group and 6.98%(3/43)in the control group,show-ing no significant difference between the two groups(χ2=0.000,P>0.05).Conclusion Bifidobacterium quadruple viable bacteria tablets combined with ulinastatin and octreotide have significant efficacy in the treatment of SAP because it can effectively reduce the inflammatory response,improve intestinal mucosal barrier function and pancreatic function,and have a certain degree of safety.
Keywords：Severe acute pancreatitisBifidobacterium quadruple viable bacteriaUlinastatinOctreotideEfficacy
Publication Date：2025-04-25
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：5( 266-270 )